drugset
Drugs / Pegylated recombinant human arginase 1
last change Oct 2016 re-read 3 minutes ago

Pegylated recombinant human arginase 1

Protein / enzyme biologic

Developed for
hepatocellular carcinoma
Investigated by
Bio-Cancer Treatment International Limited · The University of Hong Kong

Trials 1

today NCT02089633 · Ph 2
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02089633 Apr 2014 → Sep 2016 hepatocellular carcinoma Bio-Cancer Treatment International Limited Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Pegylated recombinant human arginase 1 “Pegylated recombinant human arginase 1 in combination with Oxaliplatin and Capecitabine” NCT02089633 ↗
Modality Protein / enzyme biologic “pegylated recombinant human arginase 1” NCT02089633 ↗
Route Intravenous “weekly IV PEG-BCT-100 2.7 mg/kg” NCT02089633 ↗